Algen, a spin-out from Nobel laureate Jennifer Doudna’s lab, is revolutionizing drug discovery using CRISPR and AI. Its platform AlgenBrain integrates advanced computational models with scalable, single-cell systems to decode causal disease biology and accelerate the development of next-generation therapies, leading to a $555M deal with AstraZeneca.